{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T10:53:58Z","timestamp":1764240838705,"version":"build-2065373602"},"reference-count":23,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2024,12,29]],"date-time":"2024-12-29T00:00:00Z","timestamp":1735430400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Salvage treatment options have not been validated in relapsed or refractory germ cell tumors. Moreover, the study populations including these patients have different heterogeneities. This study aimed to evaluate the efficacy and safety of three cycles of TIP sequential high-dose chemotherapy in patients with testicular non-seminomatous germ cell tumors who relapsed or had a refractory course after first-line platinum-based chemotherapy. Methods: Data of 141 patients who underwent three cycles of TIP followed by HDCT due to relapsed\/refractory gonadal NSGCTs after first-line cisplatin-based chemotherapy (BEP\/EP) at Gulhane School of Medicine Hospital Medical Oncology Department between January 2017 and May 2024 were evaluated retrospectively. Patients underwent a treatment regimen consisting of two phases. Initially, they received three cycles of induction therapy using a combination known as TIP, which includes paclitaxel, ifosfomide, and cisplatin. Following this, they were given a single cycle of high-dose chemotherapy. Demographic and clinicopathological features of patients and treatment-related complications and survival outcomes were recorded. Results: Median follow-up for all patients was 35.2 (95% CI, 29.45 to 41.07) months. Complete Response (CR) or marker negative Partial Response (PR) after HDCT was achieved in 84 (59.6%) patients. Median time for PFS not reached (NR) (95% CI, NR) in the entire group. The 2-year PFS rate was 51.8%. Median time for OS not reached (95% CI, NR) and the 2-year OS rate was 72.3%. The most common myelotoxicity observed after HDCT until engraftment was grade 4 neutropenia (100%) and grade 4 thrombocytopenia (96.5%). Transplantation-related mortality occurred in 7.1% of patients. Variables that remained statistically significant in multivariable analysis and were associated with poor prognosis for overall survival were platinum refractory disease and AFP and\/or beta HCG elevation. Conclusions: Significant survival can be achieved after three cycles of TIP consecutive HDCT, while treatment-related mortality was found to be low.<\/jats:p>","DOI":"10.3390\/jcm14010131","type":"journal-article","created":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T07:00:37Z","timestamp":1735628437000},"page":"131","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Three Cycles of TIP and Sequential High Dose Chemotherapy in Patients with Testicular Non-Seminomatous Germ Cell Tumors"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7538-9119","authenticated-orcid":false,"given":"Musa Baris","family":"Aykan","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulsema","family":"Yildiran Keskin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u0130smail","family":"Erturk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ramazan","family":"Acar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmet Fatih","family":"Kose","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nuri","family":"Karadurmus","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Health Sciences, Gulhane School of Medicine, Ankara 06018, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,12,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1200\/JCO.20.03296","article-title":"Predicting Outcomes in Men With Metastatic Nonseminomatous Germ Cell Tumors (NSGCT): Results From the IGCCCG Update Consortium","volume":"39","author":"Gillessen","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_2","first-page":"33","article-title":"Paclitaxel (Taxol) combination therapy for resistant germ cell tumors","volume":"27","author":"Motzer","year":"2000","journal-title":"Semin. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41585-022-00683-1","article-title":"High-dose chemotherapy for relapsed testicular germ cell tumours","volume":"20","author":"Chovanec","year":"2023","journal-title":"Nat. Rev. Urol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/bju.15648","article-title":"High-dose chemotherapy for relapsed germ cell tumours: Outcomes in low-volume specialized centres","volume":"130","author":"Connolly","year":"2022","journal-title":"BJU Int."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1159\/000538660","article-title":"High-Dose Chemotherapy and Autologous Stem Cell Transplantation for Salvage Therapy of Relapsed\/Refractory Germ Cell Tumors: A Single-Center Experience","volume":"47","author":"Erturk","year":"2024","journal-title":"Oncol. Res. Treat."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/bjc.2018.7","article-title":"Systemic immune-inflammation index in germ-cell tumours: Search for a biological prognostic biomarker","volume":"118","author":"Albany","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7272541","DOI":"10.1155\/2018\/7272541","article-title":"Conventional-Dose versus High-Dose Chemotherapy for Relapsed Germ Cell Tumors","volume":"2018","author":"McHugh","year":"2018","journal-title":"Adv. Urol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1177\/1078155220964540","article-title":"Treating relapsed and refractory metastatic germ cell tumours with high-dose chemotherapy with carboplatin and etoposide and autologous haematopoietic stem cell transplantation","volume":"27","author":"Erturk","year":"2021","journal-title":"J. Oncol. Pharm. Pract."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1200\/JCO.2016.69.5395","article-title":"High-Dose Chemotherapy and Autologous Peripheral-Blood Stem-Cell Transplantation for Relapsed Metastatic Germ Cell Tumors: The Indiana University Experience","volume":"35","author":"Adra","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/annonc\/mdi228","article-title":"A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours","volume":"16","author":"Pico","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1056\/NEJMoa067749","article-title":"High-dose chemotherapy and stem-cell rescue for metastatic germ-cell tumors","volume":"357","author":"Einhorn","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1200\/JCO.2009.25.1561","article-title":"TI-CE high-dose chemotherapy for patients with previously treated germ cell tumors: Results and prognostic factor analysis","volume":"28","author":"Feldman","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"3130","DOI":"10.1200\/JCO.23.02542","article-title":"Paclitaxel, Ifosfamide, and Cisplatin as Initial Salvage Chemotherapy for Germ Cell Tumors: Long-Term Follow-Up and Outcomes for Favorable- and Unfavorable-Risk Disease","volume":"42","author":"Gleeson","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"374","DOI":"10.7150\/jca.2.374","article-title":"Is high dose therapy superior to conventional dose therapy as initial treatment for relapsed germ cell tumors? The TIGER Trial","volume":"2","author":"Feldman","year":"2011","journal-title":"J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/21681805.2020.1784270","article-title":"Can we predict the development of symptomatic lymphocele following robot-assisted radical prostatectomy and lymph node dissection? Results from a tertiary referral Centre","volume":"54","author":"Sforza","year":"2020","journal-title":"Scand. J. Urol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: The next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/annonc\/mdu569","article-title":"Neutrophil-to-lymphocyte ratio as a prognostic biomarker for men with metastatic castration-resistant prostate cancer receiving first-line chemotherapy: Data from two randomized phase III trials","volume":"26","author":"Templeton","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/bjc.2017.467","article-title":"Systemic inflammatory markers have independent prognostic value in patients with metastatic testicular germ cell tumours undergoing first-line chemotherapy","volume":"118","author":"Fankhauser","year":"2018","journal-title":"Br. J. Cancer"},{"doi-asserted-by":"crossref","unstructured":"Cursano, M.C., Kopf, B., Scarpi, E., Menna, C., Casadei, C., Schepisi, G., Lolli, C., Altavilla, A., Gall\u00e0, V., and Santini, D. (2020). Prognostic Role of Systemic Inflammatory Indexes in Germ Cell Tumors Treated With High-Dose Chemotherapy. Front. Oncol., 10.","key":"ref_19","DOI":"10.3389\/fonc.2020.01325"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"880","DOI":"10.29271\/jcpsp.2022.07.880","article-title":"Efficacy of Gemcitabine, Paclitaxel, and Oxaliplatin Protocol in the Treatment of Relapsed or Refractory Germ Cell Tumours","volume":"32","author":"Aykan","year":"2022","journal-title":"J. Coll. Physicians Surg. Pak."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1038\/sj.bmt.1703008","article-title":"Double dose-intensive chemotherapy with autologous stem cell support for relapsed and refractory testicular cancer: The University of Michigan experience and literature review","volume":"27","author":"Ayash","year":"2001","journal-title":"Bone Marrow Transplant."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/(SICI)1097-0142(19970101)79:1<161::AID-CNCR23>3.0.CO;2-1","article-title":"Long-term survival of patients with recurrent or refractory germ cell tumors after high dose chemotherapy","volume":"79","author":"Beyer","year":"1997","journal-title":"Cancer"},{"doi-asserted-by":"crossref","unstructured":"Zujuan, S., Xin, D., Yang, H., and Guifu, Z. (2024). Potential Next Generation Markers of Testicular Germ Cell Tumors: miRNA-371a-3p. Int. Urol. Nephrol., 1\u201310.","key":"ref_23","DOI":"10.1007\/s11255-024-04284-2"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/131\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:55:44Z","timestamp":1760115344000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/1\/131"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,29]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["jcm14010131"],"URL":"https:\/\/doi.org\/10.3390\/jcm14010131","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2024,12,29]]}}}